Inspire Medical Systems (INSP) Price & Analysis

Compare

737 Followers

INSP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$123.25 - $225.00

Previous CloseN/A

Volume95.34K

Average Volume (3M)543.99K

Market Cap

$3.72B

Enterprise Value$4.49B

Total Cash (Recent Filing)$53.88M

Total Debt (Recent Filing)$31.49M

Price to Earnings (P/E)58.1

Beta0.75

Next Earnings

Aug 04, 2025

EPS Estimate

0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding29,493,923

10 Day Avg. Volume483,323

30 Day Avg. Volume543,988

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.21

Enterprise Value/Revenue5.35

Enterprise Value/Gross Profit6.32

Enterprise Value/Ebitda57.65

Forecast

1Y Price Target

$210.09

Price Target Upside66.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Procedure EfficiencyInspire V implantation procedure can be performed near the 20-minute mark, significantly ahead of the 45-60 minutes being marketed by the company.

Product LaunchThe Inspire V full launch was confirmed for May, helping to address concerns from some investors on a rollout being pushed to far later in the year.

Sales PerformanceInspire Medical reported a 1Q sales beat with a significant improvement in operating margin.

Bears Say

Competitive RiskLIVN's OSPREY study included patients with complete concentric collapse, whereas INSP's pivotal studies excluded these patients, potentially giving LIVN a competitive advantage.

Revenue ForecastManagement alluded to Q2 as a 'transition quarter', with dynamics like patient warehousing and Inspire IV destocking driving a softer than anticipated revenue forecast.

Sales ForecastQ2 sales are expected to be below prior expectations, with management forecasting growth lower than consensus.

Inspire Medical Systems News

Apnimed says sleep apnea drug meets primary endpoint in Phase 3 trial

Apnimed announced positive topline results from its second pivotal Phase 3 clinical trial of Apnimed’s lead candidate AD109....

12d ago

RMD

INSP

Inspire Medical price target lowered to $197 from $216 at KeyBanc

KeyBanc lowered the firm’s price target on Inspire Medical (INSP) to $197 from $216 and keeps an Overweight...

13d ago

INSP

Inspire Medical price target lowered to $182 from $200 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $182 from $200 and keeps an...

20d ago

INSP

Inspire Medical price target lowered to $149 from $176 at Leerink

Leerink lowered the firm’s price target on Inspire Medical (INSP) to $149 from $176 and keeps a Market...

21d ago

INSP

INSP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Inspire Medical (INSP) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

2d ago

INSP

Inspire Medical granted premarket application approval for CGuard Prime

Inspire Medical (INSP) announced that the FDA has granted premarket application approval of the CGuard Prime Carotid Stent...

1M ago

INSP

Buy Recommendation for Inspire Medical Systems Driven by Efficiency and Growth Potential

Morgan Stanley analyst Kallum Titchmarsh has maintained their bullish stance on INSP stock, giving a Buy rating on...

2M ago

INSP

Inspire Medical Systems Launches Inspire V for OSA

Inspire Medical Systems ( ($INSP) ) has shared an announcement. Inspire Medical Systems announced the full launch of...

2M ago

INSP

Inspire Medical Systems: Poised for Growth with Inspire 5 and SleepSync Adoption

Jefferies analyst Michael Sarcone maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) today and...

2M ago

INSP

Inspire Medical’s Earnings Call Highlights Growth and Challenges

Inspire Medical (($INSP)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

INSP

Inspire Medical falls -11.9%

Inspire Medical (INSP) is down -11.9%, or -$18.91 to $139.83. Published first on TheFly – the ultimate source...

3M ago

INSP

Inspire Medical price target lowered to $200 from $220 at Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Inspire Medical (INSP) to $200 from $220...

3M ago

INSP

Inspire Medical price target raised to $236 from $230 at Baird

Baird raised the firm’s price target on Inspire Medical (INSP) to $236 from $230 and keeps an Outperform...

3M ago

INSP

Inspire Medical price target lowered to $174 from $195 at Wells Fargo

Wells Fargo lowered the firm’s price target on Inspire Medical (INSP) to $174 from $195 and keeps an...

3M ago

INSP

INSP FAQ

What was Inspire Medical Systems’s price range in the past 12 months?

Inspire Medical Systems lowest stock price was $123.25 and its highest was $225.00 in the past 12 months.

What is Inspire Medical Systems’s market cap?

Inspire Medical Systems’s market cap is $3.72B.

When is Inspire Medical Systems’s upcoming earnings report date?

Inspire Medical Systems’s upcoming earnings report date is Aug 04, 2025 which is today.

How were Inspire Medical Systems’s earnings last quarter?

Currently, no data Available

Is Inspire Medical Systems overvalued?

According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inspire Medical Systems pay dividends?

Inspire Medical Systems does not currently pay dividends.

What is Inspire Medical Systems’s EPS estimate?

Inspire Medical Systems’s EPS estimate is 0.2.

How many shares outstanding does Inspire Medical Systems have?

Inspire Medical Systems has 29,493,923 shares outstanding.

What happened to Inspire Medical Systems’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Inspire Medical Systems?

Currently, no hedge funds are holding shares in INSP

Inspire Medical Systems Stock Smart Score

Neutral

Fundamentals

Return on Equity

10.86%

Trailing 12-Months

Asset Growth

6.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Inspire Medical Systems (INSP) Earnings & Revenues

INSP Earnings Data >

INSP Company Deck

INSP Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a strong start to the year with significant revenue growth, profitability, and a strategic launch of the new Inspire V system. However, there are some concerns about short-term revenue impacts due to transition challenges and international sales decline. Overall, the long-term outlook remains positive with increased guidance and strategic initiatives in place.Read More>

INSP Revenue Breakdown

97.02% U.S.

2.98% Other

INSP Stock 12 Month Forecast

Average Price Target

$210.09

▲(66.61%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"129":"$129","200":"$200","271":"$271","164.5":"$164.5","235.5":"$235.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":210.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$210.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":149,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$149.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[129,164.5,200,235.5,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.81,141.5169230769231,152.22384615384615,162.93076923076924,173.6376923076923,184.3446153846154,195.05153846153848,205.75846153846155,216.4653846153846,227.1723076923077,237.8792307692308,248.58615384615385,259.2930769230769,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.81,136.90846153846155,143.00692307692307,149.10538461538462,155.20384615384614,161.3023076923077,167.40076923076924,173.4992307692308,179.5976923076923,185.69615384615383,191.79461538461538,197.89307692307693,203.99153846153848,{"y":210.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,130.81,132.20923076923077,133.60846153846154,135.0076923076923,136.40692307692308,137.80615384615385,139.20538461538462,140.60461538461539,142.00384615384615,143.40307692307692,144.8023076923077,146.20153846153846,147.60076923076923,{"y":149,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":138.71,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.11,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >